secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2026-04-07T23:59:59+00:00
Accession:  0001493152-26-015451
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona Therapeutics appoints Keith Goldan as new independent Board member and Audit Committee Chair
--------------------------------------------------------------------------------

- Board expanded from 9 to 10 members; Goldan appointed as Class 1 director effective April 1, 2026.
- Goldan named Chair of Audit Committee; Board determined independence under Nasdaq rules.
- Compensation: $50,000 annual cash fee and $150,000 one-time sign-on RSU grant with one-year vesting.
- Goldan currently CFO of Syndax Pharmaceuticals; previously CFO at Optinose and Fibrocell.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000149315226015451/0001493152-26-015451-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000149315226015451/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-015451

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer